Evidence map›Paper›PMID 36879883›Full record

ArticleComputational and structural biotechnology journal2023

Drug screening and biomarker gene investigation in cancer therapy through the human transcriptional regulatory network.

Zihao He, Kai Gao, Lei Dong, Liu Liu, Xinchi Qu, Zhengkai Zou, Yang Wu, Dechao Bu, Jin-Cheng Guo, Yi Zhao

Open access · goldAbstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Exploring the anticancer potential ofJournal of advanced pharmaceutical technology & research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zihao HeSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Kai GaoSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Lei DongSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Liu LiuSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Xinchi QuSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Zhengkai ZouSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Yang WuResearch Center for Ubiquitous Computing Systems, Institute of Computing Technology, Chinese Academy of Sciences, Beijing 100190, China.
Dechao BuResearch Center for Ubiquitous Computing Systems, Institute of Computing Technology, Chinese Academy of Sciences, Beijing 100190, China.
Jin-Cheng GuoSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Yi ZhaoSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Beijing University of Chinese Medicine · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A complex and vast biological network regulates all biological functions in the human body in a sophisticated manner, and abnormalities in this network can lead to disease and even cancer. The construction of a high-quality human molecular interaction network is possible with the development of experimental techniques that facilitate the interpretation of the mechanisms of drug treatment for cancer. We collected 11 molecular interaction databases based on experimental sources and constructed a human protein-protein interaction (PPI) network and a human transcriptional regulatory network (HTRN). A random walk-based graph embedding method was used to calculate the diffusion profiles of drugs and cancers, and a pipeline was constructed by using five similarity comparison metrics combined with a rank aggregation algorithm, which can be implemented for drug screening and biomarker gene prediction. Taking NSCLC as an example, curcumin was identified as a potentially promising anticancer drug from 5450 natural small molecules, and combined with differentially expressed genes, survival analysis, and topological ranking, we obtained BIRC5 (survivin), which is both a biomarker for NSCLC and a key target for curcumin. Finally, the binding mode of curcumin and survivin was explored using molecular docking. This work has a guiding significance for antitumor drug screening and the identification of tumor markers.

Indexed as

BIRC5CurcuminDrug screeningMolecular dockingNetwork medicineTranscriptional regulatory network

Identifiers

PMID36879883
PMCPMC9984461
OpenAlexW4319339280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.